 |
 |
 |
 |
 |
|
|||||
|
Select Publications
Burger RA et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71. Abstract
Burger RA et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. Proc ASCO 2005;Abstract 5009.
Cannistra SA et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6. Abstract
De Placido S et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22(13):2635-42. Abstract
Diaz JP et al. The safety and efficacy of bevacizumab therapy in recurrent ovarian carcinoma.
Proc ASCO 2008;Abstract 16528.
Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour? J Clin Oncol 2007;25(33):5150-2. No abstract available
Markman M et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2006a;101(3):436-40. Abstract
Markman M et al. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. Proc ASCO 2006b;Abstract 5005.
Markman M et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21(13):2460-5. Abstract
McGonigle KF et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). Proc ASCO 2008;Abstract 5551.
Miller DS et al. A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. Proc ASCO 2008;Abstract 5524.
Parmar MK et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106. Abstract
Pfisterer J et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006a;24(29):4699-707. Abstract
Pfisterer J et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006b;98(15):1036-45. Abstract
Rose PG et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003;88(2):130-5. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Deborah K Armstrong, MD
- Select publications
David R Spriggs, MD
- Select publications
Robert L Coleman, MD
- Select publications
Ovarian Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
  |
